IM Cannabis Appoints Asi Levi as CFO to Enhance Financial Management
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Source: PRnewswire
- Executive Change: IM Cannabis has appointed Asi Levi as the new Chief Financial Officer, replacing Uri Birenberg, with Levi bringing over 15 years of financial management experience, which is expected to enhance the company's financial planning and budgeting capabilities.
- Experienced Leader: Levi previously served as CFO for Water Ways Technologies and DekelOil CI, possessing extensive experience in fundraising and cash flow management, which will aid IM Cannabis in achieving compliance under international financial reporting standards.
- Market Focus: IM Cannabis concentrates on the two largest medical cannabis markets, Israel and Germany, and Levi's appointment is anticipated to facilitate sustainable and profitable growth in these high-value markets.
- Strategic Goals: The company aims to amplify its commercial and brand power through a data-driven approach and a global supply chain, and Levi's addition is expected to further propel the achievement of these strategic objectives.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on IMCC
About IMCC
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IM Cannabis Corp. Secures $2.17 Million in Debt Financing
- Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through a third-party loan agreement to address liquidity needs, enhancing financial flexibility amid operational challenges.
- First Note Details: The first note issued amounts to $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and has an 18-month maturity, reflecting the company's focus on effective debt management.
- Second Note Arrangement: The second note totals $632,911 with similar terms, including an 8% interest rate and identical repayment structure, further solidifying the company's financial foundation.
- Equity Conversion Rights: Both notes are convertible into common shares at a price of $1.47 or 90% of the lowest VWAP over 20 days, providing the company with a potential equity financing avenue.
Continue Reading
IM Cannabis Corp. Secures $2.17 Million in Debt Financing
- Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through an agreement with a third-party lender to address liquidity needs, thereby enhancing financial flexibility.
- First Note Details: The company issued a first note of $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and an 18-month maturity, reflecting a cautious approach to debt management.
- Second Note Issuance: The second note amounts to $632,911.50 with the same interest rate and maturity as the first, further solidifying the company's financial foundation to support operations and strategic initiatives.
- Equity Conversion Rights: Both notes are convertible into common shares, with the first note's conversion price set at $1.47 per share, ensuring the company maintains flexibility in future financing while providing potential value appreciation for investors.
Continue Reading